0000950170-24-026001.txt : 20240305
0000950170-24-026001.hdr.sgml : 20240305
20240305162627
ACCESSION NUMBER: 0000950170-24-026001
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brandenberger Ralph
CENTRAL INDEX KEY: 0001853197
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39370
FILM NUMBER: 24720915
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 102
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nkarta, Inc.
CENTRAL INDEX KEY: 0001787400
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 474515206
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1150 VETERANS BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (925) 407-1049
MAIL ADDRESS:
STREET 1: 1150 VETERANS BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2024-03-01
0001787400
Nkarta, Inc.
NKTX
0001853197
Brandenberger Ralph
C/O NKARTA, INC.
1150 VETERANS BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Technical Officer
false
Common Stock
2024-03-01
4
M
false
3808
3.89
A
85384
D
Common Stock
2024-03-01
4
M
false
2955
3.89
A
88339
D
Common Stock
2024-03-01
4
S
false
8367
12.51
D
79972
D
Stock Option (right to buy)
3.89
2024-03-01
4
M
false
3808
0.00
D
2029-09-05
Common Stock
3808
22445
D
Stock Option (right to buy)
3.89
2024-03-01
4
M
false
2955
0
D
2029-09-05
Common Stock
2955
25629
D
The transaction reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person and most recently amended on September 2, 2022.
This transaction was executed in multiple trades at prices ranging from $12.50 to $12.58. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
The options exercised were fully vested.
The options exercised were fully vested. Unvested options will vest and become exercisable ratably in monthly installments until fully vested on July 1, 2024.
/s/ Alicia Hager, as Attorney-in-Fact
2024-03-05